- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03097575
Bronchial NIR Image-guided Resection
Bronchial NIR Image-guided Resection, Mapping And Targeted Lymphadenectomy for Lung Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients enrolled in the study will undergo peritumoral injection of near-infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery. ICG injection will be carried out via navigational bronchoscopy, CT-guided or trans-thoracic ICG injection (dependent on lesion location) and ICG imaging of the sentinel lymph nodes will be undertaken using an NIR-enabled camera.
- This study is designed primarily to determine the safety and feasibility of intra-operative localization of thoracic lesions following ICG injection, and second, to include an assessment of the predictive value of sentinel lymph nodes relative to the disease status of the greater lymphadenectomy specimen as well as disease recurrence rates.
- We are using a dose approximately 100 times lower than previously approved for injection in the blood. After a few minutes, the surgeon will look at these lymph nodes with near-infrared fluorescence and then remove any fluorescent and non-fluorescent lymph nodes near the tumor, as is standard for lung surgery.
- The "filtered" near-infrared light causes the indocyanine green dye to fluoresce so that the surgeon can identify the lymph nodes most likely to contain tumor cells. If the lymph node is not found in the group of nodes usually removed, we will use the near-infrared light to look near the tumor for the sentinel lymph nodes and guide the surgeon so that the sentinel nodes can be removed and studied. The surgeon will then continue with the operation and remove the tumor. The lymph nodes are processed for special analysis tailored to finding metastasis in sentinel lymph nodes.
- As is standard of care, patients will be monitored for evidence of recurrence by their surgeon. Recurrences will be recorded.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yolonda Colson, MD, PhD
- Phone Number: 617-726-5200
- Email: ycolson@partners.org
Study Contact Backup
- Name: Isha Mehta Warikoo, MD
- Phone Number: 18572501355
- Email: imehtawarikoo@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 01224
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Yolonda L Colson, MD, PhD
- Phone Number: 617-726-5200
- Email: ycolson@partners.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients that have agreed to undergo video assisted thoracoscopic surgery or thoracotomy for surgical resection as recommended by their thoracic surgeon.
- 18 years of age or older
- Documented, signed, dated informed consent obtained prior to any study specific procedures being performed
Exclusion Criteria:
- Pregnant women are excluded and women of childbearing potential without a negative pregnancy test prior to study procedures. All patients with Iodine allergies will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ICG Intervention
The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping.
All study subjects will receive this same intervention; there is only one arm.
|
Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
Other Names:
A near-infrared camera device will be used to detect indocyanine green following injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (safety and feasibility) of intraoperative NIR-image-guided localization of lung lesions using peritumoral ICG injection.
Time Frame: 5 years
|
In this initial proof-of-concept pilot trial for patients undergoing surgical resection of a suspicious lung lesion, we will translate the new technology of NIR-imaging to the OR and assess safety and feasibility of ICG delivery, optimize the ability to "NIR tattoo" and visualize lung lesions for targeted resection vs NIR-highlighted segmental resections, assess histology of the surgical margin and determine lesional characteristics which predict successful NIR imaging.
Safety and feasibility will be measured quantitatively by the number of participants with treatment-related adverse events, as assessed by CTCAE v4.0.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigate whether SLNs can be identified using NIR-guidance following peritumoral ICG injection.
Time Frame: 5 years
|
Technical difficulty and clinical complications have resulted in < 50% of surgeons performing complete removal of tumor draining lymph nodes at the time of surgery.
Therefore, we will assess the feasibility of SLN identification following ICG injection for "targeted" lymph node sampling and focused analysis staging.
This Outcome will be addressed only in cases where a lymphadenectomy is performed.
|
5 years
|
Assess if NIR image-guided SLN excision enhances detection of metastatic disease and whether the presence of untreated occult metastatic disease/mutational analysis of primary tumors/secondary sites of disease including SLNs are predictors of outcome
Time Frame: 5 years
|
Studies in stage I and II lung cancer have demonstrated "occult" nodal metastatic disease affects clinical outcomes, however, currently there is no accurate means to identify micrometastatic nodal disease in these patients prospectively.
Therefore, we will analyze the SLN results to determine whether prospectively identified "occult" micrometastatic disease in the SLN is a "predictor" of disease recurrence.
This Outcome is pertinent only to cases in which a lymphadenectomy was performed.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yolonda L Colson, MD, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2014P001436
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sentinel Lymph Node
-
Federation of Breast Diseases SocietiesUnknown
-
Second Affiliated Hospital of Wenzhou Medical UniversityEnrolling by invitationMRI | Sentinel Lymph Node BiopsyChina
-
Acibadem UniversityUnknown
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingSentinel Lymph NodeFrance
-
Assiut UniversityNot yet recruiting
-
Shandong Cancer Hospital and InstituteUnknownSentinel Lymph Node BiopsyChina
-
Hospital DonostiaCompletedLymphedema of Limb | Sentinel Lymph NodeSpain
-
Seoul National University HospitalNational Evidence-Based Healthcare Collaborating AgencyActive, not recruitingBreast Cancer | Sentinel Lymph NodeKorea, Republic of
-
Novadaq Technologies ULC, now a part of StrykerCompletedBreast Cancer | Sentinel Lymph Node Biopsy | Lymph Node MappingUnited States, Canada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingCervical Cancer | Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Lymph Node Disease | Lymph Node Metastases | Sentinel Lymph Node Biopsy | Endometrium Tumor | Cervical Neoplasm | Micrometastasis | Cervical TumorItaly
Clinical Trials on ICG Intervention
-
Brigham and Women's HospitalCompletedPulmonary Nodule, Solitary | Pulmonary Nodule, MultipleUnited States
-
Huazhong University of Science and TechnologyUnknownCervical Cancer | Sentinel Lymph NodeChina
-
University of AarhusAarhus University HospitalRecruitingCardiovascular Diseases | Inflammation | Lymphedema | Turner SyndromeDenmark
-
University of PennsylvaniaCompleted
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Pulsion Medical Systems SEUnknownMalignant Neoplasm of BreastGermany
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical CenterCompleted
-
Activ SurgicalRecruitingCholecystitis | Biliary Dyskinesia | CholelithiasisUnited States
-
Huazhong University of Science and TechnologyUnknown
-
Huazhong University of Science and TechnologyUnknown